Latest News
Announcements, partnerships, and milestones from the PointFit team.
Seveno Capital's strategic investment values PointFit at US $10 million, backing our non-invasive sweat patch for real-time biomarker monitoring beyond heart-rate wearables. The deal anchors Seveno's Hong Kong expansion and supports continuous lactate monitoring for athletes, with a modular platform built to scale across performance, metabolic health, and longevity care.
At ECSS 2026 in Lausanne, PointFit presented pilot study results showing 0.9547 ± 0.0327 correlation between continuous sweat lactate and capillary blood markers.
The PointFit team demonstrated the PF-sweat sensor alongside talented young triathletes at CREPS Montpellier, gathering invaluable athlete feedback in the field.
PointFit returned to VivaTech for a live Discovery Stage demonstration with Kinomap, earning coverage from AFP, Les Echos, and official VivaTech channels.
At Club Bâtard in Hong Kong, Kenny Oktavius represented PointFit on stage with Steven Bartlett, sharing how non-invasive sweat biomarker monitoring can reach more people.
Privacy policy These statements have not been evaluated by the FDA. PointFit Sweat Sensor is not intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease.